Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Stockpiling Priority Review Vouchers

Executive Summary

Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.

Advertisement

Related Content

Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Priority Review Voucher Sales Prices Level Off In 2017
Novel Biologics Will Get Suffixes (Or At Least One Did)
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine
Novartis Aims Canakinumab At Targeted CV Patients
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel